Omega-3 for Depression and Other Cardiac Risk Factors - 2

Summary

The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for major depression in patients with coronary heart disease (CHD).

Timeline

Start

2014-05-14

Primary completion

2018-09-13

Completion

2018-09-13

Outcome

Missed primary endpoint

paper After 10 weeks of treatment, there were no differences between the arms on the mean baseline-adjusted BDI-II (placebo, 10.3; EPA, 12.1; P = .22) PMID 31163106 ↗

paper Augmentation of sertraline with 2 g/d of EPA for 10 weeks did not result in greater improvement in depressive symptoms compared to sertraline and corn oil placebo PMID 31163106 ↗

Publications

• Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients With or at Risk for Coronary Heart Disease. J Clin Psychiatry. 2019 Jun 4;80(4):19m12742. doi: 10.4088/JCP.19m12742.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eicosapentaenoic acid	Small molecule	2 g	—
Background	Sertraline	Small molecule	50 mg	—

Indications